Detection of Osimertinib Resistant Mutations with Droplet Digital PCR

摘要

EGFR-mutant lung cancer is a subtype of non-small cell lung cancer (NSCLC) that exhibits sensitivity to EGFR TKIs such as gefitinib and erlotinib. However, acquired resistance develops after a median of 9-14 months. The most common mechanism of TKI resistance is a second-site mutation (T790M) in the EGFR kinase domain. Osimertinib (AZD9291) is an oral, irreversible, mutant-selective EGFR TKI developed to have potency against tumors harboring the T790M resistance mutation.